

Figure S1. EGCG might mitigate the abnormal organ measurements linked to colitis. (A) Liver weight in different treatment groups. (B) Spleen weight in different treatment groups. (C) Kidney weight in different treatment groups. (D) Liver index (liver weight/body weight ratio). (E) Spleen index (liver weight/body weight ratio). (F) Kidney index (liver weight/body weight ratio). Statistical significance is indicated as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.




Figure S2. Effects of EGCG on Inflammatory Markers IL-6, IL-1 β , and TNF- α in Colitis. (A) Serum IL-1 β content. (B) Serum IL-6 content. (C) Serum TNF- α content. Statistical significance is indicated as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.




Figure S3. EGCG Inhibits ROS and Fe²⁺ to Alleviate Ferroptosis. (A) Flow cytometry images of lipid peroxidation in MCEC. The cells were stained with 5 μ M C11-BODIPY, a dye used to detect lipid peroxidation. Flow cytometry analysis was performed to assess the positive rate of lipid peroxidation in MCEC after treatment with EGCG and RSL3. (B) Flow cytometry histogram of labile iron pool (LIP) in MCEC.